Fosamprenavir. Anti-HIV, HIV protease inhibitor

Drugs of the Future

Volumn 26, Issue 3, 2001, Pages 224-231

  Sorbera, L A ^a   Martin L ^a   Castaner J ^a   Castaner R M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANGERASE; ATAZANAVIR; DPC 681; DPC 684; INDINAVIR; KYNOSTATIN 272; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MOZENAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NAUSEA; NONHUMAN; RANDOMIZED CONTROLLED TRIAL;

EID: 0034989360     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.03.615590     Document Type: Article

References (24)

1. Discovery of VX-175/GW433908, a novel, water-soluble prodrug of amprenavir
2. Improved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine
3. Randomised placebo controlled trial of ritonavir in advanced HIV-1 disease
4. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4+ cell counts of 200 per cubic millimeter or less
5. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
6. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1
7. Rationale and experience with reverse transcriptase inhibitors and protease inhibitors
8. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailabllity in humans
9. 141W94
10. Preclinical development of GW433908/VX-175 the water-soluble phosphate prodrug of amprenavir
11. Highly polar, water-soluble prodrugs of the HIV protease inhibitor amprenavir: A new approach toward a more compact dosing regimen
12. Single-dose safety and pharmacokinetics of GW433908, a prodrug of amprenavir (141 W94, APV), administered as an oral liquid formulation to healthy male subjects
13. Food effect on single dose pharmacokinetics of GW433908G, a prodrug of amprenavir (141W94, APV) administered as a tablet to healthy male subjects
14. GW433908, a novel prodrug of the HIV protease inhibitor (PI) amprenavir (APV): Safety, efficacy, and pharmacokinetics (APV20001)